We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00477217
First Posted: May 23, 2007
Last Update Posted: September 23, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Novartis
May 22, 2007
May 23, 2007
September 23, 2016
January 2008
May 2009   (Final data collection date for primary outcome measure)
Changes from baseline after 3 months in a) knee pain scores (using the KOOS pain subscale), and b) volume of osteonecrotic lesion (indicated by bone marrow oedema) on MRI. [ Time Frame: 3 months ]
Same as current
Complete list of historical versions of study NCT00477217 on ClinicalTrials.gov Archive Site
  • Changes from baseline after 6 months in a) knee pain scores (using the KOOS pain subscale), and b) volume of osteonecrotic lesion (indicated by bone marrow oedema) on MRI. [ Time Frame: 6 months ]
  • Safety as assessed by adverse events.
Same as current
Not Provided
Not Provided
 
Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee
A Randomized, Double-blind, Placebo-controlled, Proof of Concept Study of Zoledronic Acid in Spontaneous Osteonecrosis of the Knee (SONK)
This study will assess the safety and efficacy of zoledronic acid in patients presenting with spontaneous osteonecrosis of the knee.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Osteonecrosis
Drug: Zoledronic acid
Other Name: Reclast, Aclasta
1
Intervention: Drug: Zoledronic acid
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
May 2009
May 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults 40-85 years of age
  • Diagnosis of painful osteonecrosis of the knee within the last month.

Exclusion Criteria:

  • Intravenous (iv) bisphosphonates within the last 2 years.
  • Abnormal thyroid, kidney or liver function.
  • Abnormal blood calcium or alkaline phosphatase levels.

Other protocol-defined inclusion/exclusion criteria may apply

Sexes Eligible for Study: All
40 Years to 85 Years   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Australia
 
 
NCT00477217
CZOL446HAU21
Not Provided
Not Provided
Not Provided
External Affairs, Novartis
Novartis
Not Provided
Principal Investigator: Novartis . Novartis Pharmaceuticals
Novartis
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP